Abstracts

316 – Divergent Systemic and Mucosal SARS-CoV-2 Adaptive Immunity in African Adults Without HIV

Background The upper (URT) and lower (LRT) respiratory tracts are the principal sites of SARS-CoV-2 infection and severe COVID-19 disease, respectively. While serum anti-Spike antibody levels are associated with a reduced risk of reinfection, the mechanistic correlates of airway protection remain unclear. Methods In this prospective cohort study, we recruited HIV-uninfected, COVID-19–unvaccinated adults in Blantyre,…

1061 – Oral PrEP Uptake and Continuation in Mozambique: Findings From Large Scale Implementation

Background Access to HIV pre-exposure prophylaxis (PrEP) has expanded significantly in resource-limited settings, including Mozambique, where oral PrEP was implemented at select health facilities in 2017, and nationally in 2021. Understanding patterns of oral PrEP uptake and persistence is essential to inform relevant strategies. Methods We conducted a mixed-methods evaluation to assess uptake and continuation…

915 – Neighborhood Deprivation and HIV Retention-in-Care in a Southern Metropolitan Setting

Background The environment in which people with HIV (PWH) reside plays a complex and influential role in shaping outcomes along the HIV Care Continuum. In this study, we investigated the Area Deprivation Index (ADI)—a comprehensive metric of neighborhood-level disadvantage which ranks geographic areas based on cumulative socioeconomic adversity—as a potential determinant of retention-in-care (RiC) among…

381 – Tunneling Nanotubes: A Novel Target to Prevent HIV Reactivation

Background HIV infection is initiated through the interaction of the viral envelope protein with host cell receptors CD4 and CCR5/CXCR4, facilitating viral entry. However, the mechanisms underlying viral spread after entry particularly when soluble virus is undetectable or minimal  remains poorly understood. We propose that tunneling nanotubes (TNTs), a long-range intercellular processes, mediate early viral…

491 – Optimization of Dose and Analytic Treatment Interruption for VRC07-523LS and PGT121.414.LS

Background A5388 is an ongoing phase II, randomized, double-blind, placebo-controlled study evaluating VRC07-523LS and PGT121.414.LS. These novel HIV-1 broadly neutralizing antibodies (bNAbs) are administered at antiretroviral therapy initiation in adults with acute or early HIV and an analytical treatment interruption (ATI) is planned after bNab clearance to evaluate for a vaccinal-like effect characterized by sustained virologic suppression.…

516 – Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase II Study

Background In a Phase 2 study (NCT05052996), once-weekly oral islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, plus lenacapavir (LEN), a capsid inhibitor, maintained a high rate (94.2%) of virologic suppression at Week (W) 48 in virologically suppressed (VS) adults with HIV-1. We report efficacy, safety, and adherence outcomes in all participants receiving ISL+LEN during…

548 – Time to ART Initiation After HIV Acquisition in HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Trials

Background The HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Antibody Mediated Prevention (AMP) trials demonstrated that broadly neutralizing monoclonal antibodies (bnAbs) could prevent acquisition of bnAb-sensitive HIV-1. Ensuring timely linkage to care and antiretroviral therapy (ART) initiation for participants who acquire HIV during clinical trials is critical. However, barriers to ART initiation in HIV prevention…